Pharmacogenetic Effect on the Pharmacodynamics of Glibenclamide

Shamir Medical Center (Assaf-Harofeh)

Status: Unknown

Conditions: Diabetes

Study type: Observational

Funder types: Other

Identifiers

NCT01242137

169/09

Details and patient eligibility

About

Glibenclamide is metabolized by the hepatic enzyme P450 CYP2C9 to less active form. Polymorphism of this enzyme demonstrated clinical significance when examined on other drugs from the sulfonylurea drug family, to whom Glibenclamide is included.

The investigators assumption is that patients with less active alleles of the enzyme may show lower dose requirements of the drug for glycemic control, when compared to patients homozygotes to wild-type alleles.

Enrollment: 30 estimated patients

Sex: All

Ages: 20 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Tx with metformin and glibenclamide

Exclusion criteria

• Tx which affecting the P450 2C9 action
• Renal failure

Trial design

30 participants in 3 patient groups

Extensive metabolizers

Intermediate mtabolizers

Poor metabolizers